COLLEYVILLE, TX, Apr 17 (MARKET WIRE) --
digiMedical Solutions, Inc. (PINKSHEETS: DGMS) announced today that the
Company has signed a contract with Dr. Yovanni Tineo in Naples, Florida, to
implement the digiRX system and digiReauth call center services. digiRX and
digiReauth are both proprietary, Microsoft-based applications developed by
digiMedical that provide digital prescription handling for physicians,
includingprescription reauthorization processing and refill management services.
Dr. Tineo, who has more than 5,000 patients, received her doctorate from New
York College of Osteopathic Medicine (NYCOM) of New York Institute of
Technology in Old Westbury, NY and completed her residency at Jamaica Hospital
in
Queens, NY.
Contract Follows Multiple Other Contracts in the Naples Area Increasing
Company's
Regional Footprint
The Company is actively expanding their regional footprint in the Naples
area in
support of the 2008 revenue goal of $10 million. Each new doctor contract can
add hundreds of patients to the digiRX network, who in turn drive prescription
sales in company owned pharmacies and increase company revenue.
This contract follows digiMedical's recent announcements of other
contractswith Orthopedic Surgeon Dr. Howard Kapp of Anchor Health Centers, Drs.
Santos-Ocampo, Axline and Spilker of the Collier Heart Group, the Medical
Director of Vanish Vein and Laser Center and Dr. Wey of the Neuroscience and
Spine
Associates in Naples, Florida.
digiMedical Prescription Handling Software and Pharmacies
digiMedical Solutions, a Microsoft Partner, with operations in Texas and
Florida, has built its own suite of proprietary software to handle prescriptions
digitally from the physician's office to the pharmacy, securely and in
compliance
with all DEA and HIPAA requirements. The suite of software includes digiRX,
digiRxStream, digiReauth, digiRxComp, and now digiAccounting and the Company
owns and operates five pharmacies throughout Texas and Florida.
Recent Analyst Report Coverage with Recommendation of $0.30 or Higher
Micros Report initiated research coverage of digiMedical Solutions and
issued
a report reviewing the Company's historical operations and 2008 business plan.
Michael Willingham, Micros Report Director of Research, authored the report
which
includes a Fair Value Target price for DGMS of $0.30.
In the report, Mr. Willingham stated, "digiMedical's proprietary
technologysolution positions the company to profit from both the traditional
existingpharmacy market space and the future of digital prescription
fulfillment."
The report is available at http://www.digimedical.com/news/news.aspx under
"Featured Presentation." Interested parties may also access the report by
going to the www.MicrosReport.com homepage or by emailing ir@digimedical.com and
requesting a copy.
Company Information and Updates
To be added to digiMedical's corporate e-mail list for shareholders and
interested investors or to receive more information on the company, please send
an e-mail to ir@digimedical.com.
About digiMedical Solutions, Inc.(TM)
digiMedical Solutions, Inc.(TM) (http://www.digimedical.com) is a pharmacy
and
medical technology company focused on developing next generation digital medical
technology with an emphasis on digital prescriptions (d-Prescriptions) that will
more
closely align the doctor, pharmacist and patient. The company's planned
growth will come from three channels: direct marketing of the company's wireless
base d-prescription technology to doctors, acquisition of independent
pharmacy chains and the sale of certain territories to "market partners"
licensed
to exploit the digiMedical Solutions(TM) model. digiMedical Solutions, Inc.(TM)
currently owns and operates five (5) pharmacies located in Texas and Florida.
digiMedicalSolutions'(TM) unique business model brings doctor, patients and
pharmaciesinto next generation medical technologies.
Forward-Looking Statement
Statements included in this press release which are not historical in
nature, are intended to be, and are hereby identified as "Forward-Looking
Statements" for
purposes of safe harbor provided by Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-Looking Statements may be identified by
words including "anticipate," "await," "envision," "foresee," "aim at,"
"believe,"
"intends," "estimates" including without limitation, those relating to the
company's future business prospects, are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
indicated in the Forward-Looking Statements. Readers are directed to the
company's
filings with the U.S. Securities and Exchange Commission for additional
information and a presentation of the risks and uncertainties that may
affect the company's business and results of operations.
digiMedical Solutions, Inc.
Investor Relations
ir@digimedical.com
214-722-3029
Copyright 2008, Market Wire, All rights reserved.
-0-
